The clinical candidate MTL-CEBPA leads to significant reduction in ascites and improvement in overall survival in a CCl4-induced acute liver failure model.
File(s)
Author(s)
Reebye, V
Voutila, J
Blakey, D
Habib, R
Mallappa, O
Type
Conference Paper
Date Issued
2016-10-01
Date Acceptance
2016-10-01
Citation
Hepatology, 2016, 64, pp.1045A-1046A
URI
ISSN
0270-9139
Publisher
Wiley
Start Page
1045A
End Page
1046A
Journal / Book Title
Hepatology
Volume
64
Copyright Statement
© 2016, John Wiley and Sons
Sponsor
Mina Therapeutics Ltd
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804462&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
P58698
Source
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Subjects
Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
Publication Status
Published
Start Date
2016-11-11
Finish Date
2016-11-15
Coverage Spatial
Boston, MA